Bulk Pharmaceutical API Sources for BREVIBLOC IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for BREVIBLOC IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-847-093
Hangzhou APIChem Technology		AC-6972
Oakwood Products		068021
Amadis Chemical		A840055
TimTec		SBB055181

BREVIBLOC (ESMOLOL HYDROCHLORIDE) BULK API SOURCING ANALYSIS

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sources for Brevibloc (esmolol hydrochloride), a short-acting beta-blocker used for controlling ventricular rate in supraventricular tachyarrhythmias and for perioperative hypertension and tachycardia. The analysis focuses on key manufacturers, geographic distribution, regulatory compliance, and supply chain considerations relevant to R&D and investment decisions.

WHO ARE THE PRIMARY BULK API MANUFACTURERS FOR ESMOLOL HYDROCHLORIDE?

The global supply of esmolol hydrochloride API is concentrated among a limited number of manufacturers, primarily located in Asia. Key players include:

• Hubei Biocause Pharmaceutical Co., Ltd. (China): A significant producer of cardiovascular APIs, including esmolol hydrochloride. The company operates under GMP compliance and has a substantial production capacity.
• Zhejiang NHU Co., Ltd. (China): Another major Chinese pharmaceutical ingredient manufacturer with a diverse API portfolio. NHU adheres to international quality standards.
• Other Chinese Manufacturers: Several smaller to medium-sized Chinese API producers also manufacture esmolol hydrochloride, often supplying the domestic market and acting as contract manufacturers for global pharmaceutical companies. Identifying these entities often requires direct engagement and due diligence.
• Indian Manufacturers: While less dominant than China, some Indian API companies are also capable of producing esmolol hydrochloride. These firms typically focus on niche APIs or operate through contract manufacturing arrangements. Their presence is less prominent in public disclosures compared to Chinese counterparts.

The production of esmolol hydrochloride API involves complex multi-step synthesis, requiring specialized equipment and stringent quality control to meet pharmacopeial standards. The chemical synthesis pathway typically starts from readily available precursors and involves several intermediate steps.

WHAT ARE THE GEOGRAPHIC CONCENTRATIONS OF ESMOLOL HYDROCHLORIDE API PRODUCTION?

The overwhelming majority of bulk esmolol hydrochloride API manufacturing is concentrated in China. This concentration is driven by several factors:

• Cost Competitiveness: China's established pharmaceutical manufacturing infrastructure and lower labor costs provide a significant cost advantage in API production.
• Scale of Production: Chinese manufacturers have invested heavily in large-scale production facilities, enabling them to meet global demand efficiently.
• Regulatory Environment: While evolving, China's regulatory framework has supported the growth of its API export sector. Many Chinese API manufacturers hold Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) and are inspected by the U.S. Food and Drug Administration (FDA).

India represents a secondary but smaller hub for API production, including some cardiovascular agents. However, for esmolol hydrochloride specifically, China's dominance is pronounced.

WHAT ARE THE KEY REGULATORY AND QUALITY CONSIDERATIONS FOR ESMOLOL HYDROCHLORIDE API SOURCING?

Sourcing esmolol hydrochloride API requires strict adherence to regulatory and quality standards to ensure patient safety and product efficacy. Key considerations include:

• Good Manufacturing Practices (GMP): API manufacturers must demonstrate compliance with international GMP standards, such as those set by the FDA, EMA, and WHO. This includes robust quality management systems, validated manufacturing processes, and rigorous testing procedures.
  • FDA Inspections: Manufacturers supplying to the U.S. market are subject to FDA inspections. A successful FDA inspection history is critical.
  • EDQM CEP: For European markets, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is often required.
• Pharmacopeial Compliance: The API must meet the specifications outlined in relevant pharmacopeias, including:
  • United States Pharmacopeia (USP): Esmolol Hydrochloride USP monograph.
  • European Pharmacopoeia (Ph. Eur.): Esmolol Hydrochloride Ph. Eur. monograph.
  • Japanese Pharmacopoeia (JP): Esmolol Hydrochloride JP monograph.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA DMF, ASMF in Europe). These confidential documents contain detailed information about the manufacturing process, facilities, and controls. Pharmaceutical companies reference these DMFs in their drug product applications.
  • Types of DMFs: U.S. DMFs are filed with the FDA. Active Drug Master Files (ADMFs) or Active Substance Master Files (ASMFs) are used in Europe.
• Impurity Profiling: Comprehensive understanding and control of process-related impurities and degradation products are essential. This includes identifying and quantifying known impurities and characterizing novel ones.
• Stability Data: Manufacturers must provide robust stability data for the API under various storage conditions, supporting its shelf life.

WHAT ARE THE TYPICAL SUPPLY CHAIN CHALLENGES AND RISKS ASSOCIATED WITH ESMOLOL HYDROCHLORIDE API?

The concentrated nature of esmolol hydrochloride API production, primarily in China, introduces several supply chain risks:

• Geopolitical Instability: Trade disputes, political tensions, or changes in export policies in manufacturing countries can disrupt supply.
• Environmental Regulations: Increasingly stringent environmental regulations in China can lead to temporary or permanent plant shutdowns for non-compliance, impacting production volumes and availability.
• Raw Material Shortages: Disruptions in the supply of key starting materials or intermediates, which may also be sourced from a limited number of suppliers, can halt API production.
• Logistics and Transportation: Global shipping disruptions, port congestion, and increased freight costs can affect delivery timelines and add to overall costs.
• Quality Deviations: Even with established manufacturers, unexpected quality issues or recalls can arise, leading to supply interruptions and the need for rapid requalification of alternative suppliers.
• Intellectual Property: While the primary patents for esmolol may have expired, process patents or specific polymorphic forms can still pose IP challenges for new entrants.

HOW ARE API MANUFACTURERS QUALIFIED AND MONITORED FOR ESMOLOL HYDROCHLORIDE?

Pharmaceutical companies employ a rigorous process for qualifying and monitoring API manufacturers to ensure a reliable and compliant supply chain. This typically involves:

1. Initial Screening and Due Diligence:
   • Review of company profile, financial stability, and track record.
   • Assessment of regulatory compliance history (FDA 483s, warning letters, CEP status).
   • Evaluation of technical capabilities and production capacity.
2. On-Site Audits:
   • Comprehensive GMP audits of manufacturing facilities by the pharmaceutical company's quality assurance team.
   • Evaluation of quality management systems, manufacturing processes, laboratory controls, and documentation.
3. Technical Data Review:
   • Review of the API manufacturer's Drug Master File (DMF) or equivalent documentation.
   • Assessment of impurity profiles, analytical methods, and stability data.
4. Sample Testing and Validation:
   • Independent testing of API samples from multiple batches to confirm quality and consistency.
   • Validation of the API manufacturer's analytical methods.
5. Ongoing Monitoring:
   • Regular quality agreements outlining responsibilities and expectations.
   • Periodic re-audits to ensure continued compliance.
   • Monitoring of regulatory updates and enforcement actions related to the supplier.
   • Performance tracking (on-time delivery, quality metrics).

WHAT ARE THE COMPETITIVE LANDSCAPE AND PRICING TRENDS FOR ESMOLOL HYDROCHLORIDE API?

The competitive landscape for esmolol hydrochloride API is characterized by:

• Limited Number of Major Suppliers: As detailed previously, a few large Chinese manufacturers dominate the global supply.
• Price Sensitivity: Esmolol hydrochloride is a mature product, and its price is highly sensitive to production costs and market competition.
• Contract Manufacturing: A significant portion of API supply is likely facilitated through contract manufacturing agreements, where the API manufacturer produces for multiple branded and generic drug product companies under specific terms.

Pricing Trends:

Pricing is influenced by:

• Manufacturing Scale and Efficiency: Larger producers with optimized processes can offer lower per-unit costs.
• Raw Material Costs: Fluctuations in the cost of precursors directly impact API pricing.
• Regulatory Compliance Costs: Investments in GMP compliance, facility upgrades, and regulatory submissions add to the cost base.
• Market Demand: While a critical care drug, the overall volume for esmolol hydrochloride is moderate compared to high-volume generics. Demand is relatively stable, driven by its established therapeutic use.
• Supplier Competition: Although the number of primary manufacturers is limited, competition exists, particularly among Chinese suppliers vying for global contracts.

Current estimated pricing for bulk esmolol hydrochloride API can range significantly based on volume, quality certifications (e.g., DMF status, CEP), and supplier relationships, but typically falls in the \$50 - \$150 per kilogram range. These figures are estimates and subject to market dynamics and negotiation.

WHAT ARE THE IMPLICATIONS FOR R&D AND INVESTMENT DECISIONS?

The sourcing landscape for esmolol hydrochloride API has direct implications for R&D and investment decisions:

• Supply Chain Security: For R&D projects involving esmolol hydrochloride drug products, securing a reliable and qualified API supplier early in development is paramount. Diversifying the supplier base, where feasible, can mitigate risks.
• Cost of Goods Sold (COGS): API costs are a significant component of the overall COGS for a finished drug product. Understanding current API pricing trends and potential future price volatility is crucial for financial modeling and investment projections.
• Regulatory Strategy: The choice of API supplier will directly impact the regulatory filing strategy. Ensuring the chosen supplier's DMF is robust and accepted by target regulatory agencies is essential.
• Partnership Opportunities: For API manufacturers, focusing on robust GMP compliance, expanding capacity, and obtaining necessary international certifications (CEP, successful FDA inspections) are key to capturing market share. For pharmaceutical companies, strategic partnerships with reliable API manufacturers can ensure long-term supply stability.
• Due Diligence: Any investment in companies that manufacture esmolol hydrochloride API or drug products utilizing it requires thorough due diligence on the API supply chain, including the financial health, regulatory compliance, and operational capacity of key API suppliers.

KEY TAKEAWAYS

• Esmolol hydrochloride API production is highly concentrated in China, with Hubei Biocause and Zhejiang NHU as prominent manufacturers.
• Strict adherence to GMP, pharmacopeial standards (USP, Ph. Eur.), and regulatory filings (DMFs) is non-negotiable for API sourcing.
• Supply chain risks are elevated due to geopolitical factors, environmental regulations in China, and potential raw material disruptions.
• API pricing is competitive, influenced by manufacturing scale, raw material costs, and regulatory compliance burdens, typically ranging from \$50-\$150 per kilogram.
• Securing a stable, qualified API supply chain is critical for successful R&D and investment in esmolol hydrochloride drug products.

FREQUENTLY ASKED QUESTIONS

1. What is the typical lead time for sourcing esmolol hydrochloride API from Chinese manufacturers? Lead times can vary significantly but generally range from 3 to 6 months, depending on current production schedules, order volume, and shipping logistics. Expedited orders may be possible but typically incur higher costs.

2. Are there any significant patent expiries relevant to esmolol hydrochloride API production that would facilitate new market entry? The core patents for esmolol hydrochloride have long expired, allowing for generic production. However, specific patented manufacturing processes or novel polymorphic forms could still exist, requiring thorough patent landscaping.

3. How can a company assess the quality control systems of a potential esmolol hydrochloride API supplier without an on-site audit? While on-site audits are preferred, initial assessments can be made by reviewing publicly available regulatory inspection reports (e.g., FDA warning letters, successful inspection notices), requesting detailed quality agreements, reviewing impurity profiles and analytical method validation data, and checking for CEPs or other international certifications.

4. What are the implications of environmental crackdowns in China on the future supply of esmolol hydrochloride API? Environmental regulations in China can lead to temporary plant shutdowns for compliance and, in some cases, permanent closure of non-compliant facilities. This can cause short-term supply disruptions and price volatility. Companies must monitor regulatory developments and consider diversifying their supplier base to mitigate this risk.

5. What is the role of a Drug Master File (DMF) in the procurement of esmolol hydrochloride API? A DMF provides regulatory agencies with confidential, detailed information about the API's manufacturing process, facilities, and controls. Pharmaceutical companies reference the DMF in their drug product applications (e.g., ANDA, NDA). A well-maintained and accepted DMF is crucial for timely regulatory approval of the finished drug product.

CITATIONS

[1] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Company Profile. Retrieved from company website. [2] Zhejiang NHU Co., Ltd. (n.d.). Product Portfolio. Retrieved from company website. [3] United States Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement, and Criminal Prosecutions. Retrieved from fda.gov. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from edqm.eu. [5] United States Pharmacopeia. (n.d.). Pharmacopeial Notices and Monographs. Retrieved from uspharmacopeia.org. [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from edqm.eu.